Samsung Bioepis

Pharmacists do more than just dispense medicines. They support appropriate medicine use, safe treatment delivery, and medication guidance. This #WorldPharmacistsDay, we recognize that pharmacists play a vital role in helping quality medicines reach the patients who need them. #WPD2026

Nearly 30 years of real-world evidence show that quality drift is not a problem for biosimilars. Samsung Bioepis has demonstrated lot-to-lot consistency in commercial biosimilar production for over nine years. Joseph P. Park, Senior Manager, Regulatory Strategy and Policy/External Operations, and Gillian Woollett, our VP and Head of Regulatory Strategy and Policy, address quality drift in their paper, “Why Product Drift Is Not an Issue for Biosimilars/Biologics,” published by peer-reviewed pharmacology journal BioDrugs. Learn more in their interview with Generics Bulletin: https://lnkd.in/dppXfjjQ

The first major wave of biosimilars has hit the market, injecting competition for some of the world’s most widely used medicines. Amid shifting policies that could impact that progress, what’s next for the US biosimilar market? Hear from industry experts, including our SVP and Head of US Commercial Thomas M. Newcomer, MBA in his fireside chat, at STAT’s virtual event: “Biosimilars: Have We Reached an Inflection Point?” 🔗 Mark your calendar and register at: https://lnkd.in/g_HgTPhB

Sustaining biosimilar competition requires industry-wide collaboration from policymakers, healthcare providers, and manufacturers, according to our VP and Head of Regulatory Strategy and Policy Gillian Woollett. In her Member Spotlight with the Biosimilars Forum, she emphasizes that regulatory clarity enables feasible biosimilar development. Read our latest issue of Re:Access for a deep dive into Gillian’s Biosimilars Forum Member Spotlight.

How are biosimilars addressing the rising demand for immunology treatments in Europe? Discover the long-term impact biosimilars have on patients and healthcare systems in the latest issue of Re:Access, featuring articles published in POLITICO and Euractiv.

The value of a biosimilar is more than just its price tag. Thomas M. Newcomer, MBA, our Senior VP and Head of US Commercial, explains that as it is now widely established that biosimilars have no clinically meaningful differences with their reference products, the conversation is shifting to price. He emphasizes, however, that price alone cannot inform market decisions. A holistic evaluation is critical to assessing a biosimilar's full value. To learn what biosimilars deliver from a more comprehensive standpoint, and how it shapes sustainable market decisions, read Thomas’ full interview with Pharma Boardroom here: https://lnkd.in/g56idFnU